Related Experiment Videos
OX40: targeted immunotherapy--implications for tempering autoimmunity and enhancing vaccines
1Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OR 97213, USA. aweinberg@providence.org
Trends in Immunology
|April 4, 2002
Summary
Targeting OX40 (CD134) on activated T cells enhances anti-tumor immunity by boosting cytokine production and memory T cell formation. This approach offers a promising strategy for cancer immunotherapy.
Area of Science:
- Immunology
- Molecular Biology
- Oncology
Background:
- OX40 (CD134) is a receptor on activated CD4+ T cells.
- Blocking OX40-ligand interactions can reduce autoimmunity in models.
- OX40 engagement enhances immune responses during immunization.
Purpose of the Study:
- To investigate the role of OX40 engagement in enhancing anti-tumor immunity.
- To explore the unique features of OX40 as a therapeutic target.
- To understand how OX40 influences T cell responses in inflammation.
Main Methods:
- Analysis of OX40 expression on T cells at inflammatory sites.
- Studying the effects of OX40 engagement on cytokine production.
- Evaluating the impact on antigen-specific memory T cell generation.
Main Results:
- OX40 engagement acts as a potent adjuvant, enhancing anti-tumor responses.
- It leads to increased cytokine production and memory T cell numbers.
- OX40+ T cells are recently activated and localized to inflammation sites.
Conclusions:
- OX40 is a clinically relevant target for enhancing anti-tumor immunity.
- Targeting OX40 on effector CD4+ T cells boosts immune responses without affecting the peripheral T cell repertoire.
- OX40 engagement offers a promising strategy for cancer immunotherapy.